Active Ingredient: Zanamivir
For this indication, competent medicine agencies globally authorize below treatments:
For:
In case that patient age in years is ≥ 5, respiratory (Inhalation), 10 milligrams zanamivir, 2 times daily, over the duration of 5 days.
Zanamivir is indicated for treatment of both influenza A and B in adults and children (≥5 years) who present with symptoms typical of influenza when influenza is circulating in the community.
Treatment should begin as soon as possible, within 48 hours after onset of symptoms for adults, and within 36 hours after onset of symptoms for children.
Zanamivir is for administration to the respiratory tract by oral inhalation only, using the device provided.
The recommended dose of zanamivir for treatment of influenza in adults and children from the age of 5 years is 10 mg twice daily for five days, providing a total daily inhaled dose of 20 mg.
For:
Intravenous, 600 milligrams zanamivir, 2 times daily, over the duration of 5 to 10 days.
Zanamivir is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult patients when:
Zanamivir should be used in accordance with official guidance.
Treatment with zanamivir should commence as soon as possible and usually within 6 days of the onset of symptoms of influenza.
The recommended dose is 600 mg twice daily for 5 to 10 days given by intravenous infusion.
No dose adjustment is required based on age.
Zanamivir is administered by intravenous infusion over 30 minutes.
For:
Regimen A: In case that patient age in months is ≥ 6 and patient age in years is < 6, intravenous, 14 milligrams zanamivir per kilogram of body weight, 2 times daily.
Regimen B: In case that patient age in years is ≥ 6, intravenous, 12 milligrams zanamivir per kilogram of body weight, 2 times daily.
Zanamivir is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in paediatric patients (aged ≥6 months) when:
Zanamivir should be used in accordance with official guidance.
Treatment with zanamivir should commence as soon as possible and usually within 6 days of the onset of symptoms of influenza.
Adolescents, children and infants should receive a weight-based dose regimen for 5 to 10 days.
Weight-based dose regimen by age for infants, children and adolescents with normal renal function:
| Age range | Weight-based dose regimen |
|---|---|
| 6 months to <6 years | 14 mg/kg twice daily |
| ≥6 years to <18 years | 12 mg/kg twice daily up to a maximum dose of 600 mg twice daily |
Zanamivir is administered by intravenous infusion over 30 minutes.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
